In consequence, the promotion of tumor specific TH1 CD4 activation might be an attractive therapeutic option to enhance anti–programmed cell death protein-1 and its ligand (anti–PD-1/L1) efficacy (11). The gene discussed is CD4; the disease is neoplasm.